Page 95 - Read Online

Yaroustovsky et al. Vessel Plus 2019;3:9 I http://dx.doi.org/10.20517/2574-1209.2019.02 Page 11 of 11

30. Yarustovskiy MB, Abramyan MV, Pliysch MG, Samsonova NN, Nazarova EI, et al. New medical technologies in cardiovascular surgery.
Treatment of atherosclerosis and its complications using H.E.L.P.-apheresis method. Creative Cardiology 2009;2:98-116. (in Russia)
31. Page MM, Bell DA, Hooper AJ, Watts GF, Burnett JR. Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia
in adults and children. Best Pract Res Clin Endocrinol Metab 2014;28:387-403.
32. Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, et al. Guidelines on the use of therapeutic apheresis in clinical
practice-evidence-based approach from the writing committee of the American society for apheresis: the seventh special issue. J Clin
Apher 2016;31:149-62.
33. Thompson GR, Catapano A, Saheb S, Atassi-Dumont M, Barbir M, et al. Severe hypercholesterolaemia: therapeutic goals and eligibility
criteria for LDL apheresis in Europe. Curr Opin Lipidol 2010;21:492-8.
34. Wang A, Richhariya A, Gandra ShR, Calimlim B, Kim L, et al. Systematic review of low-density lipoprotein cholesterol apheresis for
the treatment of familial hypercholesterolemia. J Am Heart Assoc 2016;5:e003294.
35. Hovland A, Marcovina S, Hardersen R, Enebakk T, Mollnes TE, et al. Three different LDL apheresis columns efficiently and equally
reduce lipoprotein(a) concentrations in patients with familial hypercholesterolemia and small apolipoprotein(a) particles. J Clin Apher
2012;46:73-6.
36. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the national heart, lung, and blood institute workshop on
lipoprotein(a) and cardiovascular disease: recent advances and future directions. Clin Chem 2003;49:1785-96.
37. Wang Y, Blessing F, Walli AK, Uberfuhr P, Fraunberger P, et al. Effects of heparin-mediated extracorporeal low-density lipoprotein
precipitation beyond lowering proatherogenic lipoproteins - reduction of circulating proinflammatory and procoagulatory markers.
Atherosclerosis 2004;175:145-50.
38. Moriarty PM, Minchew HM, Oktona DC. Treating lipoprotein(a)- hyperproteinemia and progressive cardiovascular disease with lipid-
apheresis in North America. JACC 2018;71:1784.
39. Terai N, Julius U, Haustein M, Spoerl E, Pillunat LE. The effect of low-density lipoprotein apheresis on ocular microcirculation in
patients with hypercholesterolemia: a pilot study. Br J Ophthalmol 2011;95:401-4.
40. Sinzinger H, Steiner S, Derfler K. Pleiotropic effects of regular lipoprotein-apheresis. Atheroscler Suppl 2017;30:122-27.
41. Hovland A, Lappegård KT, Mollnes TE. LDL apheresis and inflammation - implications for atherosclerosis. Scand J Immunol
2012;76:229-36.
42. Kopprasch S, Bornstein SR, Bergmann S, Graessler J, Julius U. Long-term therapeutic efficacy of lipoprotein apheresis on circulating
oxidative stress parameters - a comparison of two different apheresis techniques. Atheroscler Suppl 2015;18:80-4.
43. Hibino S, Seok YK, Tsuda H, Yonei Y. Effect of double filtration plasmapheresis (DFPP) in male patients with borderline hyper-LDL-
cholesterolemia: lipid removal and inflammation suppreesion. Anti-Aging Medicine 2009;6:32-40.
44. Hovland A, Hardersen R, Nielsen EW, Mollnes TE, Lappegård KT. Hematologic and hemostatic changes induced by different columns
during LDL apheresis. J Clin Apher 2010;25:294-300.
45. Rogova LN, Gubanova EI, Pankova GV, Shepeleva TI. Pathogenetic substantiation of the interpretation of the results of hematological
analysis of blood. Bulletin of Medical Internet Conferences 2016;6:1568-72. (in Russia)
46. Thompson GR, Barbir M, Davies D, Dobral P, Gesinde M, et al. Efficacy criteria and cholesterol targets for LDL apheresis.
Atherosclerosis 2010;208:317-21.
47. Blaha M, Ptak J, Cap J, Ceeová V, Mašín V, et al. WAA apheresis registry in the Czech Republic: two centers experience. Transfus
Apher Sci 2009;41:27-31.
48. Borberg H. 26 years of LDL - apheresis: a review of experience. Transfus Apher Sci 2009;41:49-59.
49. Henriksson MM, Newman E, Witt V, Derfler K, Leitner G, et al. Adverse events in apheresis: an update of the WAA registry data.
Transfus Apher Sci 2016;54:2-15.
50. Stegmayr B, Mörtzell Henriksson M, Newman E, Witt V, Derfler K, et al. Distribution of indications and procedures within the
framework of centers participating in the WAA apheresis registry. Transfus Apher Sci 2017;56:71-4.
51. Heigl F, Hettich R, Lotz N, Reeg H, Pflederer T, et al. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients
with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany. Atheroscler
Suppl 2015;18:154-62.
52. Geiss HC, Parhaofer KG, Donner MG, Schwandt P. Low-density lipoprotein apheresis by membrane differential filtration. The
Scientific World Journal (cascade filtration). Ther Apher Dial 1993;3:199-202.